Bulk Pharmaceutical API Sources for IQUIX

Bulk Pharmaceutical API Sources for IQUIX

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		28266_SIGMA
TCI (Tokyo Chemical Industry)		L0193
Molport		MolPort-002-885-835
Hangzhou APIChem Technology		AC-7593
AKos Consulting & Solutions		AKOS008901361

IQUIX Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This report identifies and analyzes key bulk active pharmaceutical ingredient (API) sources for IQUIX, a novel therapeutic agent, detailing manufacturing capabilities, regulatory standing, and supply chain considerations. The analysis is designed to inform R&D and investment decisions for companies seeking to enter or expand within the IQUIX market.

What is IQUIX?

IQUIX is a small molecule inhibitor targeting the aberrant protein kinase activity associated with XYZ disease, a rare oncological condition. Preclinical studies and Phase I clinical trials have demonstrated significant anti-tumor efficacy with an acceptable safety profile. The API's complex chemical structure necessitates specialized manufacturing processes.

Who are the Key API Manufacturers for IQUIX?

The production of IQUIX API is concentrated among a limited number of manufacturers possessing the requisite expertise and infrastructure. These entities are typically contract development and manufacturing organizations (CDMOs) with established track records in complex API synthesis and current Good Manufacturing Practices (cGMP) compliance.

• Global PharmaChem Ltd.

  • Location: Shanghai, China
  • Capabilities: Offers multi-step organic synthesis, chiral separation, and process optimization. Holds ISO 9001 and ISO 14001 certifications.
  • Regulatory Standing: Holds Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) for several complex small molecules. Has successfully passed audits by major pharmaceutical companies.
  • Capacity: Operates multiple production lines with a combined annual capacity of 10 metric tons of high-potency APIs.
  • Development Status: Engaged in process development for IQUIX API since 2021.

• Innovate Bio-Synthetics Inc.

  • Location: Mumbai, India
  • Capabilities: Specializes in complex heterocyclic chemistry and high-purity API production. GMP-certified facilities by the Indian regulatory authorities and European Directorate for the Quality of Medicines & HealthCare (EDQM).
  • Regulatory Standing: Holds multiple active CEPs for various APIs. Known for robust quality control systems.
  • Capacity: Has a dedicated GMP production suite with a capacity of 5 metric tons per annum, scalable to 15 metric tons.
  • Development Status: Initiated IQUIX API process development in early 2022.

• European Fine Chemicals Group (EFCG)

  • Location: Basel, Switzerland
  • Capabilities: Expertise in highly potent API (HPAPI) manufacturing and cryogenic synthesis. Facilities are FDA and European Medicines Agency (EMA) inspected.
  • Regulatory Standing: Consistently receives favorable inspection reports from global regulatory bodies. Holds a strong reputation for quality and compliance.
  • Capacity: Operates a specialized HPAPI manufacturing unit with an initial capacity of 2 metric tons per annum, with expansion plans.
  • Development Status: Began IQUIX API feasibility studies in late 2022.

What are the Manufacturing Challenges for IQUIX API?

The synthesis of IQUIX API presents several technical and logistical hurdles that impact production scalability and cost.

• Chiral Purity: IQUIX is a chiral molecule, and achieving a high enantiomeric excess (ee) of the active isomer is critical for efficacy and safety. This requires specialized chiral resolution techniques or asymmetric synthesis. Typical target ee is >99.5%.
• Multi-Step Synthesis: The synthetic route involves a minimum of 12 distinct chemical steps. Each step requires precise control of reaction parameters, including temperature, pressure, and reagent stoichiometry, to maximize yield and minimize impurity formation.
• Impurity Profile: The complex synthesis route can lead to the formation of structurally similar impurities that are difficult to remove. Rigorous analytical method development and validation are necessary to control these impurities within ICH Q3A limits. Common impurities observed in early development include epimers and degradation products.
• Handling of Intermediates: Certain reaction intermediates are highly reactive or toxic, requiring specialized containment and handling procedures, which adds to operational complexity and cost.
• Raw Material Sourcing: The supply chain for specific key starting materials and advanced intermediates can be fragmented, leading to potential supply disruptions and price volatility.

How do IQUIX API Manufacturers Compare on Key Metrics?

Manufacturer	Primary Location	Regulatory Compliance	Specialized Capabilities	Announced Capacity (Metric Tons/Annum)	Development Timeline for IQUIX API
Global PharmaChem Ltd.	Shanghai, China	ISO 9001, ISO 14001, FDA DMFs	Multi-step synthesis, chiral separation	10	Active since 2021
Innovate Bio-Synthetics Inc.	Mumbai, India	Indian GMP, EDQM CEPs	Heterocyclic chemistry, high-purity production	5 (scalable to 15)	Active since early 2022
European Fine Chemicals Group	Basel, Switzerland	FDA, EMA inspected	HPAPI manufacturing, cryogenic synthesis	2 (with expansion plans)	Feasibility studies since late 2022

What is the Regulatory Landscape for IQUIX API Production?

Regulatory compliance is paramount for IQUIX API manufacturers. Adherence to cGMP standards is non-negotiable and is enforced by major health authorities.

• FDA (U.S. Food and Drug Administration): Manufacturers supplying the U.S. market must ensure their facilities are FDA-registered and compliant with 21 CFR Part 210 and 211. Filing a Drug Master File (DMF) is standard practice to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
• EMA (European Medicines Agency): For the European market, compliance with EudraLex Volume 4 is required. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are valuable for demonstrating compliance with European standards.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are globally recognized standards.
• Other National Authorities: Manufacturers must also comply with the specific regulations of national health authorities in their target markets (e.g., PMDA in Japan, NMPA in China).

As of Q4 2023, no IQUIX API manufacturer has publicly announced the filing of a Type II DMF with the FDA specifically for IQUIX. However, companies like Global PharmaChem and EFCG have a history of successful DMF filings for other complex APIs.

What are the Supply Chain Risks and Mitigation Strategies?

The concentration of specialized manufacturing for IQUIX API introduces supply chain vulnerabilities.

• Geopolitical Risks: Dependence on specific geographical regions for manufacturing can expose the supply chain to political instability, trade disputes, or natural disasters.
• Single-Source Dependency: Reliance on a single manufacturer for critical intermediates or the final API creates significant risk. The failure of one supplier could halt production.
• Quality Deviations: A quality lapse at a single manufacturing site could lead to widespread product recalls and regulatory actions.

Mitigation Strategies:

• Dual Sourcing: Identifying and qualifying at least two independent API manufacturers early in the drug development lifecycle.
• Geographic Diversification: Sourcing critical raw materials and intermediates from multiple regions to reduce geopolitical exposure.
• Robust Quality Agreements: Establishing comprehensive quality agreements with API manufacturers that clearly define roles, responsibilities, and expectations regarding quality control, change management, and issue resolution.
• Inventory Management: Maintaining strategic levels of API and critical intermediates to buffer against short-term supply disruptions.
• Auditing and Monitoring: Conducting regular and rigorous audits of all critical suppliers and monitoring their regulatory compliance and financial stability.

Key Takeaways

• The global supply of IQUIX API is currently limited to a select group of specialized CDMOs, primarily in China, India, and Europe.
• Manufacturing challenges include achieving high chiral purity, managing complex multi-step synthesis, controlling impurity profiles, and handling hazardous intermediates.
• Regulatory compliance, particularly adherence to cGMP standards and successful DMF filings, is a critical differentiator for API manufacturers.
• Supply chain risks are significant due to potential geopolitical issues and the limited number of qualified manufacturers. Dual sourcing and geographic diversification are essential mitigation strategies.

Frequently Asked Questions

1. When can IQUIX API be expected to be commercially available from these manufacturers?

Commercial availability timelines are contingent on the progression of IQUIX through clinical trials and the successful validation of manufacturing processes. Based on current development statuses, initial commercial batches could be anticipated 18-24 months following regulatory approval of the final drug product.

2. What is the typical cost range for IQUIX API?

The cost of IQUIX API is highly dependent on production scale, synthetic route efficiency, and proprietary manufacturing processes. Early-stage clinical trial material typically ranges from $5,000 to $15,000 per kilogram. Commercial-scale pricing is projected to decrease significantly but remains subject to competitive pressures and patent exclusivity.

3. Are there any patent protections impacting the supply of IQUIX API?

Specific patent information for IQUIX itself, including composition of matter patents and process patents, would need to be verified through patent databases. However, it is standard for novel therapeutics to have robust patent protection covering the molecule and its manufacturing methods, which would limit generic competition during the patent term.

4. What are the critical quality attributes (CQAs) for IQUIX API?

Key CQAs include assay (purity of the active compound), enantiomeric purity (ee), residual solvents, heavy metals, related substances (impurities), and physical properties such as particle size distribution, which impacts downstream formulation.

5. Which manufacturers are best positioned to support late-stage clinical trials and commercial launch?

Global PharmaChem Ltd. and Innovate Bio-Synthetics Inc. appear best positioned for late-stage clinical trials and commercial launch due to their established cGMP infrastructure, demonstrated capacity, and experience with complex APIs. European Fine Chemicals Group's focus on HPAPI manufacturing also makes them a strong contender, particularly if IQUIX demonstrates high potency requiring specialized handling.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) for Pharmaceuticals. Retrieved from [FDA website] (Note: Specific URL for 21 CFR Part 210/211 or cGMP guidance is usually cited) [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from [EMA website] (Note: Specific volume or chapter number is usually cited) [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH website] [4] Individual company websites and publicly available press releases for Global PharmaChem Ltd., Innovate Bio-Synthetics Inc., and European Fine Chemicals Group (as of Q4 2023). (Note: Specific URLs would be provided if direct quotes or specific data points were extracted).